Atomistry » Sodium » PDB 4adn-4b16 » 4b05
Atomistry »
  Sodium »
    PDB 4adn-4b16 »
      4b05 »

Sodium in PDB 4b05: Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease

Enzymatic activity of Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease

All present enzymatic activity of Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease:
3.4.23.46;

Protein crystallography data

The structure of Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease, PDB code: 4b05 was solved by F.Jeppsson, S.Eketjall, J.Janson, S.Karlstrom, S.Gustavsson, L.L.Olsson, A.C.Radesater, B.Ploeger, G.Cebers, K.Kolmodin, B.M.Swahn, S.Von Berg, T.Bueters, J.Falting, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 26.33 / 1.80
Space group P 21 21 21
Cell size a, b, c (Å), α, β, γ (°) 47.529, 76.533, 104.161, 90.00, 90.00, 90.00
R / Rfree (%) 17.8 / 21.5

Other elements in 4b05:

The structure of Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease also contains other interesting chemical elements:

Fluorine (F) 3 atoms

Sodium Binding Sites:

The binding sites of Sodium atom in the Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease (pdb code 4b05). This binding sites where shown within 5.0 Angstroms radius around Sodium atom.
In total only one binding site of Sodium was determined in the Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease, PDB code: 4b05:

Sodium binding site 1 out of 1 in 4b05

Go back to Sodium Binding Sites List in 4b05
Sodium binding site 1 out of 1 in the Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease


Mono view


Stereo pair view

A full contact list of Sodium with other atoms in the Na binding site number 1 of Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease within 5.0Å range:
probe atom residue distance (Å) B Occ
A:Na1390

b:49.2
occ:1.00
 O A:HOH2160 2.4 40.8 1.0
O A:HOH2162 2.4 50.6 1.0
O A:HOH2159 2.5 40.6 1.0
O A:THR144 2.8 28.8 1.0
O A:VAL141 2.8 23.1 1.0
O A:HOH2070 3.8 53.9 1.0
C A:THR144 4.0 28.0 1.0
C A:VAL141 4.0 23.9 1.0
CA A:HIS145 4.3 28.9 1.0
CG1 A:VAL141 4.4 20.5 1.0
O A:LYS142 4.6 24.7 1.0
N A:HIS145 4.6 26.6 1.0
ND1 A:HIS145 4.7 38.0 1.0
O A:VAL146 4.8 24.4 1.0
C A:HIS145 4.8 32.8 1.0
C A:LYS142 4.8 26.3 1.0
CA A:VAL141 4.9 18.0 1.0
N A:LYS142 4.9 22.4 1.0
CA A:LYS142 4.9 23.1 1.0
N A:THR144 4.9 24.0 1.0

Reference:

F.Jeppsson, S.Eketjall, J.Janson, S.Karlstrom, S.Gustavsson, L.L.Olsson, A.C.Radesater, B.Ploeger, G.Cebers, K.Kolmodin, B.M.Swahn, S.Von Berg, T.Bueters, J.Falting. Discovery of AZD3839, A Potent and Selective BACE1 Inhibitor Clinical Candidate For the Treatment of Alzheimer Disease. J. Biol. Chem. V. 287 41245 2012.
ISSN: ESSN 1083-351X
PubMed: 23048024
DOI: 10.1074/JBC.M112.409110
Page generated: Mon Oct 7 14:26:24 2024

Last articles

Zn in 9MJ5
Zn in 9HNW
Zn in 9G0L
Zn in 9FNE
Zn in 9DZN
Zn in 9E0I
Zn in 9D32
Zn in 9DAK
Zn in 8ZXC
Zn in 8ZUF
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy